CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. Frerichs KA et al.Expert Rev Clin Immunol. 2018 Feb 21. doi: 10.1080/1744666X.2018.1443809. [Epub ahead of print]. Multinucleated giant myeloma cells after failure of daratumumab therapy. Guijarro F et al. Br J Haematol. 2018 Feb 22. doi: 10.1111/bjh.15139. [Epub ahead of print]. Defining a set of standardised outcome measures for newly diagnosed patients…
Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone. Tanimura A et al. Int J Hematol. 2018 Jan 31. doi: 10.1007/s12185-018-2408-4. [Epub ahead of print]. Phase 1/2 Trial of Carfilzomib Plus High Dose Melphalan Preparative Regimen for Salvage AHCT Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Costa LJ et al. Biol Blood…
Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Shah C et al. Leuk Lymphoma. 2018 Feb 21:1-13. doi: 10.1080/10428194.2018.1437269. [Epub ahead of print]. Acquired factor V deficiency in a patient with myeloma and amyloidosis. Quek JKS et al. Thromb Res. 2018 Jan 31;164:1-3. doi: 10.1016/j.thromres.2018.01.045. [Epub ahead of print]. Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma. Lavi N et…
The results from the Phase III ALCYONE trial have recently been published in The New England Journal of Medicine. The study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone in newly diagnosed myeloma patients, ineligible for a stem cell transplant. The results show that the 18-month progression-free survival…
Celgene has announced that its Phase III trial, OPTIMISMM, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared pomalidomide (Imnovid®) in combination with bortezomib (Velcade®) and low-dose dexamethasone to bortezomib and low-dose dexamethasone in myeloma patients who had received 1 – 3 prior treatments,…
Results from the Phase III ASPIRE trial show that carfilzomib (Kyprolis®) in combination with lenalidomide (Revlimid®) and dexamethasone has a significant overall survival (OS) benefit in relapsed and refractory myeloma patients. Recently published in the Journal of Clinical Oncology, the results demonstrate that patients receiving carfilzomib, lenalidomide and dexamethasone had a median OS of 48.3…
Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection. Kriegsmann K et al. Biol Blood Marrow Transplant. 2018 Jan 15. pii: S1083-8791(18)30022-3. doi: 10.1016/j.bbmt.2018.01.007. [Epub ahead of print]. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Anderson K et al. J Clin Oncol. 2018 Jan 17:JCO2017766402. doi: 10.1200/JCO.2017.76.6402. [Epub ahead of…
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma. Tzogani K et al. Oncologist. 2018 Jan 25. pii: theoncologist.2017-0328. doi: 10.1634/theoncologist.2017-0328. [Epub ahead of print]. Immunopathogenesis and immunotherapy of multiple myeloma. Tamura H et al. Int J Hematol. 2018 Jan 24. doi: 10.1007/s12185-018-2405-7. [Epub ahead of print]. Survival of ethnic and racial minority patients with multiple myelomatreated with newer medications.…
Prognostic Value of IL-10 and Its Relationship with Disease Stage in Iranian Patients with Multiple Myeloma. Shekarriz R et al.Asian Pac J Cancer Prev. 2018 Jan 27;19(1):27-32. Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study. Wu C et al. Acad Radiol. 2018 Jan 16. pii: S1076-6332(17)30518-4. doi: 10.1016/j.acra.2017.12.008.…
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. Dhakal B et al. JAMA Oncol. 2018 Jan 4. doi: 10.1001/jamaoncol.2017.4600. [Epub ahead of print]. Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Gertz MA et al. Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012. Prolonged survival after second autologous transplantation and lenalidomide maintenance…